145 related articles for article (PubMed ID: 18814765)
1. [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes].
Scheen AJ; Paquot N; Van Gaal LF
Rev Med Suisse; 2008 Aug; 4(168):1812-7. PubMed ID: 18814765
[TBL] [Abstract][Full Text] [Related]
2. The endocannabinoid system: a promising target for the management of type 2 diabetes.
Scheen AJ
Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
[TBL] [Abstract][Full Text] [Related]
3. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
4. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of cannabinoid receptors and glucose metabolism.
Scheen AJ; Paquot N
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid-1 receptor antagonists in type-2 diabetes.
Scheen AJ
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
[TBL] [Abstract][Full Text] [Related]
8. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Scheen AJ; Paquot N
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):103-16. PubMed ID: 19285264
[TBL] [Abstract][Full Text] [Related]
9. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
Lafontan M; Piazza PV; Girard J
Diabetes Metab; 2007 Apr; 33(2):85-95. PubMed ID: 17418607
[TBL] [Abstract][Full Text] [Related]
10. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
[TBL] [Abstract][Full Text] [Related]
11. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
12. [Three studies in type 2 diabetes: SERENADE the rimonabant (a blocker of the CB 1 receptors) in monotherapy in type 2 diabetes].
Roussel R
Ann Endocrinol (Paris); 2007 Jun; 68 Suppl 1():33-5. PubMed ID: 17961659
[No Abstract] [Full Text] [Related]
13. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.
Rosenstock J; Hollander P; Chevalier S; Iranmanesh A;
Diabetes Care; 2008 Nov; 31(11):2169-76. PubMed ID: 18678611
[TBL] [Abstract][Full Text] [Related]
14. Contribution of CB1 blockade to the management of high-risk abdominal obesity.
Després JP; Lemieux I; Alméras N
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S44-52. PubMed ID: 16570106
[TBL] [Abstract][Full Text] [Related]
15. [The endocannabinoid system].
Sudano I; Périat D; Noll G
Praxis (Bern 1994); 2008 Apr; 97(7):375-80. PubMed ID: 18548817
[TBL] [Abstract][Full Text] [Related]
16. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
Gelfand EV; Cannon CP
J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306
[TBL] [Abstract][Full Text] [Related]
17. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.
Mohapatra J; Sharma M; Singh S; Pandya G; Chatterjee A; Balaraman R; Patel PR; Jain MR
J Pharm Pharmacol; 2009 Nov; 61(11):1493-8. PubMed ID: 19903374
[TBL] [Abstract][Full Text] [Related]
18. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
19. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
Dibble CT; Gelfand EV; Cannon CP
Curr Atheroscler Rep; 2007 Nov; 9(5):359-66. PubMed ID: 18001618
[TBL] [Abstract][Full Text] [Related]
20. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice.
Nam DH; Lee MH; Kim JE; Song HK; Kang YS; Lee JE; Kim HW; Cha JJ; Hyun YY; Kim SH; Han SY; Han KH; Han JY; Cha DR
Endocrinology; 2012 Mar; 153(3):1387-96. PubMed ID: 22234468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
